Outlook Therapeutics, INC 10-Q quarterly reports

Outlook Therapeutics reports Q2 2026 financial results, highlighting ongoing commercialization in Europe and continued regulatory efforts for ONS-5010 in the U.S. amid going concern warnings.

Outlook Therapeutics reports initial European revenue for LYTENAVA but faces substantial doubt about its ability to continue as a going concern, necessitating further financing.

Outlook Therapeutics resubmitted its BLA for ONS-5010/LYTENAVA and is awaiting an FDA decision by August 27, 2025, while preparing for a potential EU/UK launch in Q2 2025.

Outlook Therapeutics reports a net income of $17.4 million for the quarter ended December 31, 2024, while navigating financial uncertainties and pursuing regulatory approval for its lead product candidate, LYTENAVA.

Outlook Therapeutics announced its Q3 2024 financial results, highlighted the European and UK marketing authorizations for LYTENAVA, and provided updates on its ongoing clinical trials for ONS-5010.

Outlook Therapeutics reported a significant net loss for the second quarter of 2024 and faces substantial doubt about its ability to continue as a going concern, despite a positive opinion from the European Medicines Agency for its lead product candidate.

Outlook Therapeutics reported its financial results for the quarter ended December 31, 2023, and provided updates on its clinical and regulatory progress for ONS-5010.